Andrographolide inhibits melanoma tumor growth by inactivating the TLR4/NF-κB signaling pathway

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The Toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB) signaling pathway is implicated in tumor progression.
• Andrographolide (Andro) exhibits anticancer properties across various cancer types, but its role in melanoma requires further investigation.

Purpose of the Study:

• To define the anticancer effects of Andrographolide (Andro) in melanoma.
• To elucidate the underlying mechanisms of Andro's action in melanoma, focusing on the TLR4/NF-κB pathway.

Main Methods:

• In vivo and in vitro experiments were conducted to assess Andro's impact on melanoma.
• Analysis included tumor growth, metastasis, cell cycle arrest, apoptosis, and the modulation of the TLR4/NF-κB signaling pathway.
• Gene and protein expression levels of CXCR4 and Bcl-6 were evaluated.

Main Results:

• Andrographolide (Andro) significantly inhibited melanoma tumor growth and metastasis.
• Andro induced cell cycle arrest and apoptosis in melanoma cells.
• Andro suppressed the TLR4/NF-κB signaling pathway, leading to reduced expression of CXCR4 and Bcl-6.

Conclusions:

• The TLR4/NF-κB signaling pathway is a potential therapeutic target for melanoma treatment.
• Andrographolide (Andro) exerts its anticancer effects in melanoma, at least partly, through the inhibition of the TLR4/NF-κB pathway.
• Targeting the TLR4/NF-κB pathway may be crucial for Andro-mediated anticancer activity in melanoma.